Friday 6-13-2014 Inovio Pharmaceuticals (INO) $INO opened at 8.85 hitting the high price of 8.94 and a day low of 8.60 with a total volume of 1,081,507. INO had a previous close of 8.81 and has been seeing an average volume of 2,065,238.
Overall Average: 48% Sell
Recent stock forum discussions about INO http://investorshangout.com/search?q=INO&...mp;yt0=Go!
Why Wall Street Hates Inovio Pharmaceuticals
George Budwell, The Motley Fool - Motley Fool - Wed Jun 11, 4:01PM CDT
Because short-sellers take on substantially more risk than individuals long a stock, they tend to be some of the more sophisticated and informed investors in the marketplace. So when they decide to jump into a stock with both feet, it's probably a... (full story)
Inovio Pharmaceuticals (INO) Marked As A Dead Cat Bounce Stock
at The Street - Wed Jun 11, 8:45AM CDT
Trade-Ideas LLC identified Inovio Pharmaceuticals (INO) as a "dead cat bounce" (down big yesterday but up big today) candidate (full story)
Inovio Pharmaceuticals Clarifies Facts of its VGX-3100 Phase II Trial and Immunotherapy Technology
PR Newswire - Wed Jun 11, 8:00AM CDT
Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) wishes to clarify that a third party article published on June 10, 2014, was misrepresentative of facts and can only be taken as malicious. The referenced article does not reflect the progress, status, and potential of Inovio's active immune therapy technology and products and is rife with false and misleading conjecture. (full story)
Inovio Pharmaceuticals (INO) Falls: Stock Plunges 13.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jun 11, 7:50AM CDT
Make sure to keep an eye on Inovio Pharmaceuticals going forward to see if this recent slump will continue, as the earnings picture definitely suggests that this might be the case. (full story)
Why Inovio Pharmaceuticals, Francesca's Holdings, and Coupons.com Tumbled Today
Dan Caplinger, The Motley Fool - Motley Fool - Tue Jun 10, 7:34PM CDT
The stock market took a pause in its strong recent performance, with the Dow rising to new record heights but the S&P 500 falling back by a fraction of a point. Investors are weighing concerns about the sustainability of the bull market in stocks... (full story)
Why Inovio Pharmaceuticals (INO) Stock Rose, Then Plunged Today (Update)
at The Street - Tue Jun 10, 3:24PM CDT
Inovio Pharmaceuticals (INO) rose in morning trading but plunged in the afternoon after a report that CEO Joseph Kim is trying to curb expectations for upcoming trial results. (full story)
Inovio CEO Preps Retail Investors for Drug Study Failure
at The Street - Tue Jun 10, 11:23AM CDT
Inovio Pharmaceuticals CEO Joseph Kim is walking back expectations for the phase II study of its DNA vaccine VGX-3100 in women with high-grade cervical intraepithelial neoplasia (CIN 2/3), also known as cervical pre-cancerous lesions. Results from... (full story)
Strength Seen in Inovio (INO): Stock Rises 9.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jun 10, 8:46AM CDT
Inovio (INO) was a big mover last session, with shares rising over 9% on the day. (full story)
Inovio Pharmaceuticals Initiates Immune Therapy Trial for Head & Neck Cancer Caused by HPV
PR Newswire - Tue Jun 10, 3:00AM CDT
Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) today announced it has initiated a phase I/IIa clinical trial to evaluate safety, immunogenicity and clinical responses of its immunotherapy product, INO-3112, in treating human papillomavirus (HPV)- associated head and neck cancer. INO-3112 is a combination of Inovio's lead active immunotherapy product, VGX-3100, and its proprietary immune activator expressing interleukin-12 (IL-12). VGX-3100 is currently being evaluated in a randomized phase II efficacy trial for the treatment of high grade cervical dysplasia (pre-cancer). (full story)
Today's Top Biotech Stocks: GW Pharmaceuticals, Inovio Pharmaceuticals and Novavax, Inc.
George Budwell, The Motley Fool - Motley Fool - Fri Jun 06, 7:45AM CDT
Let's take a look at today's top stories in biotech and health care. Keep an eye out for GW Pharmaceuticals , Inovio Pharmaceuticals and Novavax Shares of GW Pharmaceuticals are up close to 6% in premarket trading this morning after the... (full story)
Inovio Pharmaceuticals sets 5 June 2014 as its reverse common stock split date
M2 - Mon Jun 02, 6:02AM CDT
Vaccines company Inovio Pharmaceuticals (NYSE MKT:INO) disclosed on Friday that its one for four reverse stock split shall become effective at 17:00 on 5 June 2014. (full story)
Today's Top Stories in Health Care: Inovio Pharmaceuticals, MannKind Corp. NewLink Genetics and Retr
George Budwell, The Motley Fool - Motley Fool - Fri May 30, 8:00AM CDT
Let's take a look at today's top stories in biotech and health care. Keep an eye out for Inovio Pharmaceuticals , MannKind Corp. , NewLink Genetics and Retrophin . Inovio announces date for reverse split Clinical stage vaccinemaker... (full story)
Inovio Pharmaceuticals to implement its reverse common stock split on 5 June 2014
M2 - Fri May 30, 3:41AM CDT
Vaccines company Inovio Pharmaceuticals (NYSE MKT:INO) on Friday said that its one-for-four reverse stock split will become effective at 17:00 on 5 June 2014. (full story)
Inovio Pharmaceuticals Announces Reverse Stock Split Date
PR Newswire - Fri May 30, 3:00AM CDT
Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) today announced that its previously announced 1-for-4 reverse stock split shall become effective at 5 P.M., Thursday, June 5, 2014, and trading of the Company's common stock on a post-reverse split basis shall commence on Friday, June 6, 2014. The common stock will continue to trade under the symbol "INO." (full story)
Inovio Pharmaceuticals divests its animal health assets through its subsidiary
M2 - Tue May 27, 4:34AM CDT
Vaccines company Inovio Pharmaceuticals (NYSE MKT:INO) reported on Tuesday the completion of the sale of its animal health assets. (full story)
Inovio Pharmaceuticals Subsidiary Sells Animal Health Assets
PR Newswire - Tue May 27, 3:00AM CDT
Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) today announced that its 90%-owned subsidiary, VGX Animal Health, Inc. (VAH), has concluded an agreement for the sale of its animal health assets to Plumbline Life Sciences, Inc. (PLS) of Korea. The assets being transferred include an exclusive license with Inovio for animal applications of its growth hormone-releasing hormone (GHRH) technology and animal DNA vaccines plus a non-exclusive license to Inovio electroporation delivery systems. VGX Animal Health will receive $2 million in cash in multiple payments and 20% of the outstanding shares of PLS. VAH's 20% equity ownership position in PLS will be maintained without dilution up to $10 million of additional equity fundraising by PLS. Inovio Pharmaceuticals will receive milestone payments and royalties on product sales. Inovio retains the human applications of its GHRH technology. (full story)
Inovio Pharmaceuticals Breakthrough DNA-Based Monoclonal Antibody Therapy Completely Protects Animals From Lethal Viral Challenge
PR Newswire - Tue May 27, 3:00AM CDT
Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that its novel DNA-based therapeutic monoclonal antibody targeting Chikungunya virus (CHIKV) completely protected mice from a lethal CHIKV challenge. In this preclinical study, a prototype DNA plasmid construct encoding for a monoclonal antibody for CHIKV envelope protein was created using Inovio's patented DNA optimization technology and delivered with its CELLECTRA® device. The results were presented as a poster at the 17th Annual Meeting of the American Society of Gene & Cell Therapy in Washington, DC. (full story)
Why Aeropostale, Inovio Pharmaceuticals, and Aruba Networks Tumbled Today
Dan Caplinger, The Motley Fool - Motley Fool - Fri May 23, 7:35PM CDT
Friday was a good day for the stock market on the whole, as the S&P 500 moved above 1,900 for the first time ever, and major-market benchmarks gained ground across the board. Yet, despite some of the persistently favorable trends that have helped... (full story)
Today's Top Health Care Stocks to Watch: PTC Therapeutics, Inovio Pharmaceuticals and Keryx Biopharm
George Budwell, The Motley Fool - Motley Fool - Fri May 23, 7:47AM CDT
Let's take a look at today's top stories in biotech and health care. Keep an eye out for PTC Therapeutics , Inovio Pharmaceuticals and Keryx Biopharmaceuticals . PTC shares skyrocket after positive CHMP opinion for DMD drug PTC shares are... (full story)
Inovio Pharmaceuticals' board approves one for four reverse split
M2 - Fri May 23, 5:34AM CDT
Vaccine company Inovio Pharmaceuticals (NYSE MKT:INO) said on Friday that its shareholders approved the proposal of a one for four reverse split of its common stock at its Annual General Meeting held on 22 May 2014. (full story)
Overall Average: 48% Sell
Recent stock forum discussions about INO http://investorshangout.com/search?q=INO&...mp;yt0=Go!
Why Wall Street Hates Inovio Pharmaceuticals
George Budwell, The Motley Fool - Motley Fool - Wed Jun 11, 4:01PM CDT
Because short-sellers take on substantially more risk than individuals long a stock, they tend to be some of the more sophisticated and informed investors in the marketplace. So when they decide to jump into a stock with both feet, it's probably a... (full story)
Inovio Pharmaceuticals (INO) Marked As A Dead Cat Bounce Stock
at The Street - Wed Jun 11, 8:45AM CDT
Trade-Ideas LLC identified Inovio Pharmaceuticals (INO) as a "dead cat bounce" (down big yesterday but up big today) candidate (full story)
Inovio Pharmaceuticals Clarifies Facts of its VGX-3100 Phase II Trial and Immunotherapy Technology
PR Newswire - Wed Jun 11, 8:00AM CDT
Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) wishes to clarify that a third party article published on June 10, 2014, was misrepresentative of facts and can only be taken as malicious. The referenced article does not reflect the progress, status, and potential of Inovio's active immune therapy technology and products and is rife with false and misleading conjecture. (full story)
Inovio Pharmaceuticals (INO) Falls: Stock Plunges 13.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jun 11, 7:50AM CDT
Make sure to keep an eye on Inovio Pharmaceuticals going forward to see if this recent slump will continue, as the earnings picture definitely suggests that this might be the case. (full story)
Why Inovio Pharmaceuticals, Francesca's Holdings, and Coupons.com Tumbled Today
Dan Caplinger, The Motley Fool - Motley Fool - Tue Jun 10, 7:34PM CDT
The stock market took a pause in its strong recent performance, with the Dow rising to new record heights but the S&P 500 falling back by a fraction of a point. Investors are weighing concerns about the sustainability of the bull market in stocks... (full story)
Why Inovio Pharmaceuticals (INO) Stock Rose, Then Plunged Today (Update)
at The Street - Tue Jun 10, 3:24PM CDT
Inovio Pharmaceuticals (INO) rose in morning trading but plunged in the afternoon after a report that CEO Joseph Kim is trying to curb expectations for upcoming trial results. (full story)
Inovio CEO Preps Retail Investors for Drug Study Failure
at The Street - Tue Jun 10, 11:23AM CDT
Inovio Pharmaceuticals CEO Joseph Kim is walking back expectations for the phase II study of its DNA vaccine VGX-3100 in women with high-grade cervical intraepithelial neoplasia (CIN 2/3), also known as cervical pre-cancerous lesions. Results from... (full story)
Strength Seen in Inovio (INO): Stock Rises 9.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jun 10, 8:46AM CDT
Inovio (INO) was a big mover last session, with shares rising over 9% on the day. (full story)
Inovio Pharmaceuticals Initiates Immune Therapy Trial for Head & Neck Cancer Caused by HPV
PR Newswire - Tue Jun 10, 3:00AM CDT
Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) today announced it has initiated a phase I/IIa clinical trial to evaluate safety, immunogenicity and clinical responses of its immunotherapy product, INO-3112, in treating human papillomavirus (HPV)- associated head and neck cancer. INO-3112 is a combination of Inovio's lead active immunotherapy product, VGX-3100, and its proprietary immune activator expressing interleukin-12 (IL-12). VGX-3100 is currently being evaluated in a randomized phase II efficacy trial for the treatment of high grade cervical dysplasia (pre-cancer). (full story)
Today's Top Biotech Stocks: GW Pharmaceuticals, Inovio Pharmaceuticals and Novavax, Inc.
George Budwell, The Motley Fool - Motley Fool - Fri Jun 06, 7:45AM CDT
Let's take a look at today's top stories in biotech and health care. Keep an eye out for GW Pharmaceuticals , Inovio Pharmaceuticals and Novavax Shares of GW Pharmaceuticals are up close to 6% in premarket trading this morning after the... (full story)
Inovio Pharmaceuticals sets 5 June 2014 as its reverse common stock split date
M2 - Mon Jun 02, 6:02AM CDT
Vaccines company Inovio Pharmaceuticals (NYSE MKT:INO) disclosed on Friday that its one for four reverse stock split shall become effective at 17:00 on 5 June 2014. (full story)
Today's Top Stories in Health Care: Inovio Pharmaceuticals, MannKind Corp. NewLink Genetics and Retr
George Budwell, The Motley Fool - Motley Fool - Fri May 30, 8:00AM CDT
Let's take a look at today's top stories in biotech and health care. Keep an eye out for Inovio Pharmaceuticals , MannKind Corp. , NewLink Genetics and Retrophin . Inovio announces date for reverse split Clinical stage vaccinemaker... (full story)
Inovio Pharmaceuticals to implement its reverse common stock split on 5 June 2014
M2 - Fri May 30, 3:41AM CDT
Vaccines company Inovio Pharmaceuticals (NYSE MKT:INO) on Friday said that its one-for-four reverse stock split will become effective at 17:00 on 5 June 2014. (full story)
Inovio Pharmaceuticals Announces Reverse Stock Split Date
PR Newswire - Fri May 30, 3:00AM CDT
Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) today announced that its previously announced 1-for-4 reverse stock split shall become effective at 5 P.M., Thursday, June 5, 2014, and trading of the Company's common stock on a post-reverse split basis shall commence on Friday, June 6, 2014. The common stock will continue to trade under the symbol "INO." (full story)
Inovio Pharmaceuticals divests its animal health assets through its subsidiary
M2 - Tue May 27, 4:34AM CDT
Vaccines company Inovio Pharmaceuticals (NYSE MKT:INO) reported on Tuesday the completion of the sale of its animal health assets. (full story)
Inovio Pharmaceuticals Subsidiary Sells Animal Health Assets
PR Newswire - Tue May 27, 3:00AM CDT
Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) today announced that its 90%-owned subsidiary, VGX Animal Health, Inc. (VAH), has concluded an agreement for the sale of its animal health assets to Plumbline Life Sciences, Inc. (PLS) of Korea. The assets being transferred include an exclusive license with Inovio for animal applications of its growth hormone-releasing hormone (GHRH) technology and animal DNA vaccines plus a non-exclusive license to Inovio electroporation delivery systems. VGX Animal Health will receive $2 million in cash in multiple payments and 20% of the outstanding shares of PLS. VAH's 20% equity ownership position in PLS will be maintained without dilution up to $10 million of additional equity fundraising by PLS. Inovio Pharmaceuticals will receive milestone payments and royalties on product sales. Inovio retains the human applications of its GHRH technology. (full story)
Inovio Pharmaceuticals Breakthrough DNA-Based Monoclonal Antibody Therapy Completely Protects Animals From Lethal Viral Challenge
PR Newswire - Tue May 27, 3:00AM CDT
Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that its novel DNA-based therapeutic monoclonal antibody targeting Chikungunya virus (CHIKV) completely protected mice from a lethal CHIKV challenge. In this preclinical study, a prototype DNA plasmid construct encoding for a monoclonal antibody for CHIKV envelope protein was created using Inovio's patented DNA optimization technology and delivered with its CELLECTRA® device. The results were presented as a poster at the 17th Annual Meeting of the American Society of Gene & Cell Therapy in Washington, DC. (full story)
Why Aeropostale, Inovio Pharmaceuticals, and Aruba Networks Tumbled Today
Dan Caplinger, The Motley Fool - Motley Fool - Fri May 23, 7:35PM CDT
Friday was a good day for the stock market on the whole, as the S&P 500 moved above 1,900 for the first time ever, and major-market benchmarks gained ground across the board. Yet, despite some of the persistently favorable trends that have helped... (full story)
Today's Top Health Care Stocks to Watch: PTC Therapeutics, Inovio Pharmaceuticals and Keryx Biopharm
George Budwell, The Motley Fool - Motley Fool - Fri May 23, 7:47AM CDT
Let's take a look at today's top stories in biotech and health care. Keep an eye out for PTC Therapeutics , Inovio Pharmaceuticals and Keryx Biopharmaceuticals . PTC shares skyrocket after positive CHMP opinion for DMD drug PTC shares are... (full story)
Inovio Pharmaceuticals' board approves one for four reverse split
M2 - Fri May 23, 5:34AM CDT
Vaccine company Inovio Pharmaceuticals (NYSE MKT:INO) said on Friday that its shareholders approved the proposal of a one for four reverse split of its common stock at its Annual General Meeting held on 22 May 2014. (full story)
